AbCellera Appoints Andrew Booth to its Board of Directors

October 18, 2016

AbCellera announces the appointment of life sciences executive Andrew Booth to its Board

Vancouver, Canada (October 18, 2016) – AbCellera is pleased to announce it has appointed Andrew Booth to its Board of Directors. Andrew currently serves as Chief Financial Officer for Vancouver-based STEMCELL Technologies Inc., Canada’s largest biotechnology company. STEMCELL is a global leader that supports life science research and biotechnology with a wide range of specialty cell culture media, cell separation technologies, and accessory products.

Andrew joined STEMCELL in 2010 to lead the formation of the Instrumentation Division and became CFO in 2013. Prior to STEMCELL, Andrew spent 7 years at General Electric in Koln, Paris, New York, Florence and London in a variety of positions, culminating in leading GE Healthcare’s Business Development activities for Europe, Middle East, & Africa and GE Healthcare’s Life Sciences business. Andrew is a graduate of GE’s Experienced Commercial Leadership Program and has an MBA from INSEAD in France.

In connection with Andrew’s appointment, Daniel Hunt has completed his role on the board.

“Andrew has proven himself as a prominent and respected leader in Canada’s life science community. He brings complementary experience across finance and operations, and we have full confidence in his abilities and judgement,” said Dr. Carl Hansen, President and CEO of AbCellera.

“We would like to recognize the excellent contributions Dan Hunt has made to the building of AbCellera and express our sincere thanks for his service.”

About AbCellera Biologics Inc.

AbCellera is a privately held biotechnology company that provides enabling technologies for the discovery and development of monoclonal antibody (mAb) therapies directly from natural immune cells.

AbCellera’s lead technology is a proprietary single-cell antibody discovery platform that provides pharma and biotech partners with the ability to rapidly identify mAb therapeutic candidates from the natural immune repertoires of any species, including humans. For more information, please visit

Media Contacts

Dr. Kevin Heyries Telephone: 604.827.4151 Email: